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Abstract
Following a request from the European Commission, the EFSA Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and
efﬁcacy of Calsporin® when used in feed for sows and piglets. The additive contains viable spores of a
single strain of Bacillus subtilis. This species is considered by EFSA to be suitable for the qualiﬁed
presumption of safety (QPS) approach to safety assessment, which requires the identity of the strain
to be conclusively established, evidence that the strain is not toxigenic and that it does not show
resistance to antibiotics of human and veterinary importance. The strain was found to meet the criteria
for the QPS approach in the context of previous opinions and since concerns are not expected from
other components of the additive, Calsporin® is presumed safe for all target species, consumers and
the environment. In a previous opinion, the FEEDAP Panel concluded that Calsporin® is not a dermal/
eye irritant or a skin sensitiser but should be considered a potential respiratory sensitiser. Use of the
additive in feed for sows and suckling piglets will not introduce hazards for users not already
considered. Three trials performed with sows over a complete reproductive cycle and their offspring
showed positive effects on zootechnical parameters of sows and piglets. Therefore, Calsporin® has the
potential to improve one or more performance parameters of sows and suckling piglets when
supplemented to both sows and suckling piglets at 3 9 108 CFU/kg of complete feedingstuffs. In the
view of the FEEDAP Panel, the effects observed can predominantly be traced back to the
administration of the additive to pregnant/lactating sows. The proportion of effects which could be
related to feeding supplemented creep feed to suckling piglets cannot be quantiﬁed.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from Calpis Co. Ltd.2 for authorisation of the product
Calsporin® (Bacillus subtilis DSM 15544), when used as a feed additive for sows and suckling piglets
(category: Zootechnical additives; functional group: gut ﬂora stabilisers).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from the
applicant the technical dossier in support of this application. The particulars and documents in support
of the application were considered valid by EFSA as of 7 July 2015.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product Calsporin® (Bacillus subtilis DSM 15544), when used under the proposed conditions of use
(see Section 3.2).
1.2. Additional information
The additive Calsporin® is a preparation containing viable spores of a single strain of
Bacillus subtilis. EFSA has issued several opinions on the safety and efﬁcacy of this product when used
with chickens for fattening (EFSA, 2006, 2007a), with weaned piglets (EFSA FEEDAP Panel, 2010a),
with turkeys for fattening, ducks, geese, pigeons and other game birds for meat production, ducks,
geese, pigeons, game birds, ornamental and sporting birds for rearing to point of lay, turkeys reared for
breeding and chickens reared for laying (EFSA FEEDAP Panel 2010b), with laying hens and minor avian
species for laying (EFSA FEEDAP Panel, 2015a) and with ornamental ﬁsh (EFSA FEEDAP Panel, 2015b).
The additive is currently authorised for use with chickens for fattening,3 weaned piglets,4 chickens
reared for laying, turkeys, minor avian species and other ornamental and game birds,5 and laying hens
and ornamental ﬁsh.5
The species B. subtilis is considered by EFSA to be suitable for the qualiﬁed presumption of safety
(QPS) approach to establishing safety for the target species, consumers and the environment (EFSA,
2007b; EFSA BIOHAZ Panel, 2013). This approach requires the identity of the active agent to be
established and the absence of toxigenic potential and susceptibility to a selected range of antibiotics
to be demonstrated.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier6 in support of the authorisation request for the use of Calsporin® (Bacillus subtilis DSM 15544)
as a feed additive. The technical dossier was prepared following the provisions of Article 7 of
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 On 26 January 2016, the applicant communicated the change from Calpis Co. Ltd. to Asahi Calpis Wellness Co. Ltd., represented in
the European Union by Asahi Calpis Wellness Co. Ltd. Europe Representative Ofﬁce. 46 rue Paul Valery, 75116, Paris, France.
3 Commission Regulation (EC) No 1444/2006 of 29 September 2006 concerning the authorisation of Bacillus subtilis C-3102
(Calsporin) as a feed additive. OJ L 271, 30.9.2006, p. 19 plus amendments.
4 Commission Regulation (EU) No 333/2010 of 22 April 2010 concerning the authorisation of a new use of Bacillus subtilis
C-3102 (DSM 15544) as a feed additive for weaned piglets (holder of authorisation Calpis Co. Ltd. Japan, represented in the
European Union by Calpis Co. Ltd. Europe Representative Ofﬁce). OJ L 102, 23.4.2010, p. 19.
5 Commission Regulation (EU) No 184/2011 of 25 February 2011 concerning the authorisation of Bacillus subtilis C-3102 (DSM 15544)
as a feed additive for chickens reared for laying, turkeys, minor avian species and other ornamental and game birds (holder of
authorisation Calpis Co. Ltd Japan, represented by Calpis Co. Ltd Europe Representative Ofﬁce). OJ L 53, 26.2.2011, p. 33.
6 FEED dossier reference: FAD-2015-0018.
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Regulation (EC) No 1831/2003, Regulation (EC) No 429/20087 and the applicable EFSA guidance
documents.
The European Union Reference Laboratory (EURL) considered that the conclusions and
recommendations reached in the previous assessment are valid and applicable for the current
application.8
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Calsporin® is
in line with the principles laid down in Regulation (EC) No 429/2008, the relevant guidance
documents: Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012) and Technical guidance on
tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011a).
3. Assessment
Calsporin® is a preparation of viable spores of a single strain of Bacillus subtilis intended for use as
a zootechnical additive (gut ﬂora stabiliser) in feeds for sows, in order to have beneﬁt in piglets, and
for suckling piglets.
3.1. Characterisation
The additive is a preparation of viable spores of Bacillus subtilis DSM 155449 at a minimum
declared concentration of 1 9 1010 colony-forming units (CFU)/g additive. It has the same formulation
and method of manufacture as that considered in previous applications (EFSA, 2006, EFSA FEEDAP
Panel, 2010a,b, 2015a,b). Thus, the data pertaining to composition, impurities, physical properties and
shelf life still apply.
Although no speciﬁc data on stability in feed for the target species or ability to mix in such feed
was provided, the data on mixing and stability in premixes, mash and pelleted feeds variously
produced for chickens for fattening, turkeys and piglets is considered sufﬁcient given the similarity in
feed formulation.
3.2. Conditions of use
Calsporin® is proposed to be used simultaneously in feeds for sows during the whole reproductive
cycle and for suckling piglets at a minimum recommended dose of 3 9 108 CFU/kg of complete
feedingstuffs.
3.3. Safety
The species B. subtilis is considered by EFSA to be suitable for the QPS approach to establishing
safety for the target species, consumers and the environment (EFSA, 2007b; EFSA BIOHAZ Panel,
2013). In a previous opinion (EFSA FEEDAP Panel, 2015a), the identiﬁcation of the strain and
compliance with the QPS qualiﬁcations were conﬁrmed. Therefore, the Panel concluded that
Bacillus subtilis DSM 15544 can be presumed safe for target animals, consumers of products derived
from animals fed the additive and the environment. The Panel considers these conclusions to apply
also in the current assessment. No concerns are expected from other excipients present in the
product, so Calsporin® is also considered safe for target animals, consumers and the environment.
In a previous opinion on the use of Calsporin® in feed for chickens for fattening, the
Panel concluded that the additive is not a dermal/eye irritant or a skin sensitiser but should be
considered a potential respiratory sensitiser (EFSA, 2006). The use of the additive in sows and suckling
piglets is considered unlikely to introduce hazards for users of the product not already considered as
part of the ﬁrst assessment. Therefore, the conclusions reached in the previous assessment apply to
the current application.
7 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
8 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/default/files/FinRep-FAD-2009-0013.pdf
9 C-3102 is an in-house identiﬁer; the active agent is Bacillus subtilis DSM 15544 and is referred to like this throughout this
opinion.
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3.4. Efﬁcacy
Three efﬁcacy studies, conducted in three Member States in which Calsporin® was added
simultaneously to feed for sows and suckling piglets, were submitted.
The detailed designs of the studies are presented in Table 1 and the results in Table 2. The studies
considered sows homogeneously distributed (based on parity) into two treatments: a control group
receiving a basal diet with no supplementation and a group receiving the same basal diet with
Calsporin® from insemination until weaning of the offspring. The exception was study 2 which was
developed in two consecutive cycles from weaning/service until weaning/service (cycle 1: duration of
170 days including 30 days before insemination, gestation and lactation; and cycle 2: duration of
140 days). The ﬁrst cycle involved 55 sows and the second the 44 sows that remained after the
exclusion of nine sows culled (four from the control group and ﬁve from the treated group) and two
sows removed (from the control group) due to a late return to oestrus. In all cases, the offspring was
maintained in the same groups and cross-fostering within treatments was done within 1–2 days to
equalise litters. Piglets were fed mash creep ad libitum from 7 to 10 days of age until weaning. The
additive was administered as top-dressing in a dose corresponding to 30 mg/kg based on total daily
feed intake; to reach the intended dose of 3 9 108 CFU/kg of complete feed. Controls received the
same amount of top-dressing but without added Calsporin®. Concentration in the top-dressing and/or
feeds was conﬁrmed by analysis. The parameters measured on the sows were: back fat, body weight,
body score (only in study 3), daily feed intake, number of piglets born alive/dead and number of
piglets weaned. Those on the litters were: weight of piglets at birth, after cross-fostering and at
weaning, feed intake, morbidity and mortality. In addition, faecal samples were collected on a daily
basis from piglets in all studies and from sows in studies 2 and 3 to monitor faecal consistency. In
study 1, faecal sows’ samples were collected from 10 sows/treatment at day 0, at 10 days after
moving to farrowing unit (115 days) and at weaning. Faecal scores were determined using a 5-scale
basis with 1 denoting no incidence of diarrhoea and higher values indicating increasing incidence/
severity). Data on sows’ health and performance, feed intake and piglets’ mortality were analysed
using an analysis of variance (ANOVA). Since study 1 involved sows of two consecutive batches, the
model also included the ﬁxed effects of the batches. In trial 2, data from the two cycles were analysed
independently. Tukey’s test was used to compare means for treatments. Each sow with her litter
represented an experimental unit.
In the ﬁrst study, weight loss of sows during the farrowing/suckling period was signiﬁcantly lower
in the Calsporin® group when compared to control (Calsporin® = 40.2 vs control = 46.1 kg,
respectively; p = 0.034).10 Back fat thickness and faecal consistency were not affected by treatment.
Piglets mortality to weaning was signiﬁcantly reduced when Calsporin® was supplemented
simultaneously in lactating sows’ and piglets’ feed. Piglet birth weights, weight at weaning, weight
gain (birth-weaning) and the other parameters measured, such as diarrhoea incidence, were not
affected by treatment.
At the end of the ﬁrst cycle of study 2, feed consumption of sows in the farrowing/suckling period
was signiﬁcantly higher for Calsporin® sows than for control (Calsporin®: 247.8 kg vs control:
219.1 kg, p < 0.005).11 Calsporin® sows weighed more than control sows (Calsporin®: 207.0 kg vs
control: 191.8 kg, p = 0.077), which was conﬁrmed by a signiﬁcantly lower weight loss during the
farrowing/suckling period (Calsporin®: 35.0 kg vs control: 46.9 kg; p < 0.005). Moreover, Calsporin®
sows tended to have more back fat at study end compared to control sows (Calsporin®: 10.59 vs
control: 9.41 mm, respectively; p = 0.071). The weaning–oestrus interval (period between weaning
and mating) was signiﬁcantly shorter for Calsporin® sows compared with control sows (Calsporin®: 5.3
vs control: 6.5 days; p = 0.004). Piglet mortality did not signiﬁcantly differ between groups (Table 2).
Piglets of the Calsporin® group showed a signiﬁcantly greater daily weight gain and weight at weaning
than piglets in the control group. None of the other parameters measured was inﬂuenced by
treatment. In the second cycle, study parity (control = 4.2 vs Calsporin® = 4.2) and the initial weight
of the sows (control = 238.1 kg vs Calsporin® = 236.9 kg) were similar among groups, some
signiﬁcant differences in sows’ feed intake, bodyweight and back fat losses and in litter weight at birth
and weaning and number of piglets weaned were observed between control and Calsporin® groups.
The statistical analysis of the two cycles was done independently. However, the results of the second
10 Technical dossier/Section IV/Annex IV.3.1.
11 Technical dossier/Section IV/Annexes IV.3.2 and IV.3.3.
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cycle are not considered to be independent from the ﬁrst, and thus, can only be used as supportive
evidence.
In study 3, weight loss during the lactation period was signiﬁcantly lower in the Calsporin® sows
group when compared to control sows (Calsporin® = 7.8 kg vs control = 17.7 kg; p < 0.01).12 Back fat
thickness (Calsporin® = 14.4 mm vs control = 12.8 mm, respectively; p = 0.05), body condition score
at weaning (Calsporin® = 3.24 vs control = 3.12, respectively; p = 0.01) and back fat loss during
lactation (Calsporin® = 0.86 mm vs control = 1.98 mm, respectively; p < 0.001) were also positively
and signiﬁcantly affected by treatment. No other parameters for sows were affected. The Calsporin®
group showed slightly heavier litters at birth (Calsporin®: 21.1 kg vs control: 20.3 kg; p = 0.458) and
after cross-fostering (Calsporin®: 20.1 kg vs control: 19.7 kg; p = 0.553) than the control group, but
these differences did not reach signiﬁcance until weaning. No other litter parameters measured were
inﬂuenced by treatment except for faecal score (Calsporin = 3.6 vs control = 3.5, p = 0.06), but this
difference is not considered to be of biological relevance.
In the three studies, the simultaneous supplementation of Calsporin® at the recommended dose to
sows and piglets positively and signiﬁcantly affected at least one parameter in sows (reduction in
weight loss in three studies, greater back fat thickness in two studies) and in piglets (reduced mortality
in one study and increased weight at weaning in the other two studies).
Table 1: Details on the study design for the studies performed in sows
Study Breed (parity)
Sows per
treatment(a)
Calsporin®
(CFU/kg
feed)
Duration
(days)
Sows’ basal
diets (main
ingredients)
Creep feed (main
ingredients)(time, from
day to day)
1 Hybrid (1–5) 24 0
3 9 108
136 Wheat/barley/
maize/
beat pulp
Whey powder/oat
ﬂakes/wheat bran
(10–20)
2A
2B
Large
White x Landrace
(1–10, av. 3.3–3.6)
(2–11, av. 4.2–4.2)
27/28
21/23
0
3 9 108
170
140
Wheat/maize/
soybean
meal
Maize/barley/whey
powder/wheat bran
(8–28/30)
3 Danbred (2–5) 25 0
3 9 108
140 Barley/wheat/
soybean
meal
Wheat/soybean meal/
skimmed milk powder/rolled
oats
(7–25)
CFU: colony-forming unit.
(a): Control/treatment in each cycle of study 2.
Table 2: Summary of the overall performance results on suckling piglets of the three trials
Trial
no
Treatment
(CFU/kg
feed)
No of
piglets
born alive
No of piglet
after cross-
fostering
No of
piglets
weaned
Piglet body
weight at
birth (kg)
Piglet body
weight at
weaning
(kg)
Piglet
weight gain
(g/day)
Mortality from
cross-
fostering to
weaning (%)
1 0 16.3 14.5 13.5 1.34 5.28 207 7.3b
3 9 108 15.3 14.0 13.5 1.35 5.15 195 3.4a
2A 0 12.3 12.2 11.2 1.58 7.46a 195.0a 8.4
3 9 108 12.3 12.0 11.2 1.55 8.09b 217.0b 6.3
2B 0 12.2 11.1a 1.37a 7.64a 236.1 9.1
3 9 108 12.6 11.9b 1.50b 8.08b 244.0 5.7
3 0 14.8 14.1 13.7 1.38 6.65a 208.0 3.0
3 9 108 15.1 14.1 13.7 1.39 6.99b 220.8 2.9
CFU: colony-forming unit.
a,b: Means with different superscript differ signiﬁcantly at p < 0.05.
12 Technical dossier/Supplementary information October 2016/Annex IV.3.4
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3.5. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation13 and Good
Manufacturing Practice.
4. Conclusions
The active agent fulﬁls the requirements of the QPS approach to the assessment of safety and no
concerns are expected from other components of the additive. Consequently, Calsporin® can be
presumed safe for the target animals, consumers of products from treated animals and the environment.
The additive is not a dermal/eye irritant or a skin sensitiser but should be considered a potential
respiratory sensitiser. Use of the additive in feed for sows and suckling piglets will not introduce
hazards for users not already considered.
Three trials performed with sows over a complete reproductive cycle and with their offspring
showed positive effects on zootechnical parameters of sows and piglets. Therefore, Calsporin® has the
potential to improve one or more performance parameters of sows and of suckling piglets when
supplemented to both sows and suckling piglets at 3 9 108 CFU/kg of complete feedingstuffs.
In the view of the FEEDAP Panel, the effects observed can predominantly be traced back to the
administration of the additive to pregnant/lactating sows. The proportion of effects which could be
related to feeding supplemented creep feed to suckling piglets cannot be quantiﬁed.
Documentation provided to EFSA
1) CALSPORIN®. Bacillus subtilis C-3102, DSM 15544. 2/2015. Submitted by Calpis Co. Ltd.
2) CALSPORIN®. Bacillus subtilis C-3102, DSM 15544. Supplementary information October
2016. Submitted by Asahi Calpis Wellness Co. Ltd.
3) Comments from Member States.
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